HSBC expects an operational turnaround for Biocon, driven by major biosimilar launches and a rebound in generics sales. The brokerage sees several factors supporting future earnings growth, including the FDA’s clearance of Biocon’s Malaysia plant, which alleviates previous GMP concerns.
